A Multi-center, Randomized, Pilot Trial to Evaluate the My Hematology Oncology Patient Experience (MYHOPEâ„¢) for Multiple Myeloma (MM) Digital Care Network in Patients With MM
A Multi-center, Randomized, Pilot Trial to Evaluate the My Hematology Oncology Patient Experience (MYHOPEâ„¢) for Multiple Myeloma (MM) Digital Care Network in Patients With MM
NDS-MM-004 is a multi-center, randomized, pilot trial to evaluate the MyHOPE for multiple myeloma (MM) Platform in patients with MM. The MyHOPE for MM Platform is a validated investigational device manufactured by Amalgam Rx, Inc. and designed to provide patients with a comprehensive set of tools and resources to support the patient throughout their overall experience with MM.
Inclusion Criteria:
Patient is ≥ 18 years old with a diagnosis of Multiple Myeloma
Patient must reside in the USA.
Patients within each of the following subgroups, at one of the following timepoints, will be eligible for entry:
Exclusion Criteria: